FDA warned telehealth seller Zeuss that its website misbrands compounded tirzepatide by implying Zeuss makes it and that it is FDA-approved.
What happened
FDA reviewed the website getzeuss.com in December 2025 and found it offering compounded tirzepatide drug products. The pictured labels show the name "Zeuss," which suggests Zeuss is the compounder, and FDA says Zeuss is not. The site also claimed the drugs are "FDA approved," offered "Proven Weight Loss," and said each batch is "rigorously tested for efficacy and safety."
What FDA found
The label shows the name "Zeuss" even though Zeuss does not make the drug, which falsely tells buyers Zeuss is the manufacturer.
FDCA section 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)The website calls the products "FDA approved," but compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Claims like "Proven Weight Loss" and "each batch rigorously tested for efficacy and safety" imply the products were shown safe and effective when they were not.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Selling these misbranded drugs across state lines is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells Zeuss to take immediate action, and within 15 working days to send a written response describing the steps taken to fix the violations and prevent them from recurring. The response should name the entities that actually make the products, include sample labeling, and address or remove the misleading website claims.
Who should pay attention
- telehealth platforms that sell compounded GLP-1 drugs
- compounding pharmacies whose products are resold under another company's name
- marketers who put their own name on drug labels
This is a summary. Read the original letter on fda.gov.